Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.
BMC Nephrol
; 16: 175, 2015 Oct 29.
Article
en En
| MEDLINE
| ID: mdl-26510587
ABSTRACT
BACKGROUND:
Cinacalcet is used to treat secondary hyperparathyroidism among hemodialysis patients. Large-scale epidemiologic studies describing patterns of cinacalcet use, effects on parathyroid hormone (PTH), calcium, and phosphorous levels, and predictors of discontinuation have not been previously reported.METHODS:
This retrospective cohort study used a clinical database of a large U.S. dialysis provider (2007-2010) merged with administrative data from the United States Renal Data System. Among new users of cinacalcet with Medicare coverage, trends in PTH, calcium, and phosphorus were measured in 30-day intervals following cinacalcet initiation.RESULTS:
Seventeen thousand seven hundred sixty-three eligible initiators contributed 111,047 30-day follow-up intervals. Of these, 56 % discontinued cinacalcet by month 4. Of those discontinuing, 76.3 % reinitiated. Mean values of PTH, calcium, and phosphorus decreased to recommended levels within 4 months following initiation. Proximal PTH levels < 150 pg/mL were associated with discontinuation HR = 1.23 (95 % CI 1.12, 1.36), whereas low calcium (< 7.5 mg/dL) was suggestive of an association, HR = 1.09 (95 % CI 0.91, 1.32). Being in the Part D gap period increased discontinuation risk HR = 1.09 (95 % CI 1.03, 1.16). Low-income subsidy status decreased discontinuation risk HR = 0.77 (95 % CI 0.69, 0.86). Predictors of reinitiation included low-income subsidy, HR = 1.32 (95 % CI 1.22, 1.43); higher albumin level, HR = 1.23 (95 % CI 1.10, 1.36) and higher calcium level, HR = 1.26 (95 % CI 1.19, 1.33).CONCLUSIONS:
Substantial and expected declines in laboratory values occurred following cinacalcet initiation. Early discontinuation and reinitiation of cinacalcet were common and may have occurred for clinical and economic reasons.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Cobertura del Seguro
/
Medicare Part D
/
Calcimiméticos
/
Cinacalcet
/
Hiperparatiroidismo Secundario
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
País/Región como asunto:
America do norte
Idioma:
En
Revista:
BMC Nephrol
Año:
2015
Tipo del documento:
Article
País de afiliación:
Estados Unidos